Verona Pharma plc — Director's Dealing 2024

Aug 6, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2024-08-01

Reporting Person: Hahn Mark W (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-01	Ordinary Shares	F	88544	$2.8325	Disposed	14854488	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.

F3: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on July 31, 2024 divided by eight (8).

F4: Consists of (i) 2,825,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 353,125 ADSs); and (ii) 12,029,488 Ordinary Shares underlying 1,503,686 ADSs.